TRIPSTAR

Prioritizing oral triptan treatment attributes in migraine management

P. J. Goadsby, David William Dodick, M. D. Ferrari, D. C. McCrory, P. Williams

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Migraine can be associated with severe pain and is often very disabling. Optimal treatment should provide rapid and sustained, complete pain relief, be well tolerated and restore normal function. The seven commercially available triptans show differences in performance on individual treatment attributes. The TRIPSTAR multiattribute decision model compares the profiles of the oral triptans, using efficacy and tolerability data weighted for importance, to identify if measurable differences are clinically relevant. Application of the TRIPSTAR model was demonstrated at the Migraine Trust International Symposium 2002, where delegates collectively prioritized treatment attributes according to the needs of a specific patient case history. The TRIPSTAR model identified the preferred triptans for this patient. These three triptans, almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg, standout in a triptan meta-analysis, three TRIPSTAR surveys and in a demonstration of the TRIPSTAR model at a symposium in the USA. Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice.

Original languageEnglish (US)
Pages (from-to)137-143
Number of pages7
JournalActa Neurologica Scandinavica
Volume110
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Tryptamines
Migraine Disorders
Therapeutics
Pain
Meta-Analysis

Keywords

  • Comparison
  • Ideal treatment
  • Migraine
  • Multiattribute model
  • Triptans

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

TRIPSTAR : Prioritizing oral triptan treatment attributes in migraine management. / Goadsby, P. J.; Dodick, David William; Ferrari, M. D.; McCrory, D. C.; Williams, P.

In: Acta Neurologica Scandinavica, Vol. 110, No. 3, 09.2004, p. 137-143.

Research output: Contribution to journalArticle

Goadsby, P. J. ; Dodick, David William ; Ferrari, M. D. ; McCrory, D. C. ; Williams, P. / TRIPSTAR : Prioritizing oral triptan treatment attributes in migraine management. In: Acta Neurologica Scandinavica. 2004 ; Vol. 110, No. 3. pp. 137-143.
@article{5f01a05976d247dab6da85a6da84d64a,
title = "TRIPSTAR: Prioritizing oral triptan treatment attributes in migraine management",
abstract = "Migraine can be associated with severe pain and is often very disabling. Optimal treatment should provide rapid and sustained, complete pain relief, be well tolerated and restore normal function. The seven commercially available triptans show differences in performance on individual treatment attributes. The TRIPSTAR multiattribute decision model compares the profiles of the oral triptans, using efficacy and tolerability data weighted for importance, to identify if measurable differences are clinically relevant. Application of the TRIPSTAR model was demonstrated at the Migraine Trust International Symposium 2002, where delegates collectively prioritized treatment attributes according to the needs of a specific patient case history. The TRIPSTAR model identified the preferred triptans for this patient. These three triptans, almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg, standout in a triptan meta-analysis, three TRIPSTAR surveys and in a demonstration of the TRIPSTAR model at a symposium in the USA. Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice.",
keywords = "Comparison, Ideal treatment, Migraine, Multiattribute model, Triptans",
author = "Goadsby, {P. J.} and Dodick, {David William} and Ferrari, {M. D.} and McCrory, {D. C.} and P. Williams",
year = "2004",
month = "9",
doi = "10.1111/j.1600-0404.2004.00310.x",
language = "English (US)",
volume = "110",
pages = "137--143",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - TRIPSTAR

T2 - Prioritizing oral triptan treatment attributes in migraine management

AU - Goadsby, P. J.

AU - Dodick, David William

AU - Ferrari, M. D.

AU - McCrory, D. C.

AU - Williams, P.

PY - 2004/9

Y1 - 2004/9

N2 - Migraine can be associated with severe pain and is often very disabling. Optimal treatment should provide rapid and sustained, complete pain relief, be well tolerated and restore normal function. The seven commercially available triptans show differences in performance on individual treatment attributes. The TRIPSTAR multiattribute decision model compares the profiles of the oral triptans, using efficacy and tolerability data weighted for importance, to identify if measurable differences are clinically relevant. Application of the TRIPSTAR model was demonstrated at the Migraine Trust International Symposium 2002, where delegates collectively prioritized treatment attributes according to the needs of a specific patient case history. The TRIPSTAR model identified the preferred triptans for this patient. These three triptans, almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg, standout in a triptan meta-analysis, three TRIPSTAR surveys and in a demonstration of the TRIPSTAR model at a symposium in the USA. Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice.

AB - Migraine can be associated with severe pain and is often very disabling. Optimal treatment should provide rapid and sustained, complete pain relief, be well tolerated and restore normal function. The seven commercially available triptans show differences in performance on individual treatment attributes. The TRIPSTAR multiattribute decision model compares the profiles of the oral triptans, using efficacy and tolerability data weighted for importance, to identify if measurable differences are clinically relevant. Application of the TRIPSTAR model was demonstrated at the Migraine Trust International Symposium 2002, where delegates collectively prioritized treatment attributes according to the needs of a specific patient case history. The TRIPSTAR model identified the preferred triptans for this patient. These three triptans, almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg, standout in a triptan meta-analysis, three TRIPSTAR surveys and in a demonstration of the TRIPSTAR model at a symposium in the USA. Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice.

KW - Comparison

KW - Ideal treatment

KW - Migraine

KW - Multiattribute model

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=4344605993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344605993&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2004.00310.x

DO - 10.1111/j.1600-0404.2004.00310.x

M3 - Article

VL - 110

SP - 137

EP - 143

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 3

ER -